ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 718

Mesenchymal Stem Cells and Skin Fibroblasts Both Suppress Early Steps In T Cell Activation In a Nitric-Oxide Dependent Manner

Runsheng Wang1, Francoise Meylan2, Jizhong Zou3, Mahendra Rao3 and Richard M. Siegel4, 1NIH/NIAMS, Rheumatology fellowship and training branch, Bethesda, MD, 2NIH/NIAMS, autoimmunity branch, Bethesda, MD, 3NIH/NIAMS, center for regenerative medicine, Bethesda, MD, 4National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: fibroblasts and mesenchymal stem cells, T cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: T-cell Biology and Targets in Autoimmune Disease: Signaling Pathways in T-cell Differentiation

Session Type: Abstract Submissions (ACR)

Background/Purpose: Mesenchymal stem cells (MSCs) are multipotent cells with capacity to differentiate into osteoblasts, chondrocytes, and adipocytes.  A phase II study in Europe has shown intravenous infusion of ex vivoexpanded MSCs might be an effective treatment for steroid-resistant, acute graft-versus-host disease.  This result raised the question of whether a similar therapy would be beneficial for autoimmune diseases.  Although some studies have shown that MSCs can suppress T cell proliferation, the mechanism (s) by which MSCs suppress T cell function are not well understood.  Also, whether the immunosuppressive functions of MSCs are unique to MSCs or a more general function of stromal cells has been questioned. The purpose of this study is to compare the suppressive effect of MSCs from different sources and skin fibroblasts (FB) on T cell activation, proliferation and differentiation, and to examine whether the underlying mechanisms by which suppression occurs are similar.  

Methods: Purified mouse TCRβ+ CD44- CD62Lhigh näive T cells were activated with anti-CD3/anti-CD28 antibodies, either alone or in transwell contact-independent co-cultured with human adipose derived stem cells (ADSC), human bone marrow stromal cells (BMSC), human fibroblasts (FB), human umbilical vein endothelial cells (HUVEC).  T cell activation and proliferation was analyzed using carboxyfluorescein diacetate succinimidyl ester (CFSE) and FlowJo software. T cell surface markers, intracellular cytokine expression, MSCs and FB surface markers were analyzed by flow cytometry. 

Results: ADSC and BMSC, but not FB, demonstrate trilineage differentiation potentials. After three days of co-culture of naïve T cells with ADSC, BMSC, FB or HUVEC, proliferation analysis showed that the percentage of divided cells (division index) was lower in ADSC, BMSC, FB groups compared to T-cell-only group and HUVEC group. However, after T cells had divided at least once, no difference in the further cell division (proliferation index) was observed. This indicates that ADSC, BMSC and FB suppress either activation or commitment to enter the cell cycle, rather than proliferation of activated T cells. Stromal cells needed to be present during the first 24 hours of T cell activation, and could not suppress T cell proliferation when added after that.  By using sorted Foxp3–T cells, the suppressive effect of stromal cells on T cell proliferation was shown to be independent of Treg.  Analysis of naïve CD8 T cells showed similar results.  L-NAME, an inhibitor of inducible nitric oxide synthetase (iNOS) reversed the suppressive effects of BMSC, ADSC and FB at a concentration of 50µM.

Conclusion: Mesenchymal stem cells (ADSC and BMSC) and fibroblasts can suppress T cell activation independent of Treg at a stage prior to the first cell division.   This suppression can be reversed by inhibition of iNOS.  These results indicate that immunomodulatory function is not unique to MSCs, and may be unrelated to their “stemness”. Stromal cells with different tissue origins such as skin-derived fibroblasts probably share similar properties.


Disclosure:

R. Wang,
None;

F. Meylan,
None;

J. Zou,
None;

M. Rao,
None;

R. M. Siegel,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/mesenchymal-stem-cells-and-skin-fibroblasts-both-suppress-early-steps-in-t-cell-activation-in-a-nitric-oxide-dependent-manner/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology